- Home
- NECB vs CRDF Comparison
NECB vs CRDF Comparison
Compare NECB & CRDF Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NECB
- CRDF
- Stock Information
- Founded
- NECB 1934
- CRDF 1999
- Country
- NECB United States
- CRDF United States
- Employees
- NECB N/A
- CRDF N/A
- Industry
- NECB Savings Institutions
- CRDF Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- NECB Finance
- CRDF Health Care
- Exchange
- NECB Nasdaq
- CRDF Nasdaq
- Market Cap
- NECB 263.6M
- CRDF 196.2M
- IPO Year
- NECB N/A
- CRDF N/A
- Fundamental
- Price
- NECB $23.65
- CRDF $2.63
- Analyst Decision
- NECB
- CRDF Strong Buy
- Analyst Count
- NECB 0
- CRDF 4
- Target Price
- NECB N/A
- CRDF $12.00
- AVG Volume (30 Days)
- NECB 38.3K
- CRDF 1.1M
- Earning Date
- NECB 04-21-2025
- CRDF 05-20-2025
- Dividend Yield
- NECB 3.15%
- CRDF N/A
- EPS Growth
- NECB 0.72
- CRDF N/A
- EPS
- NECB 3.44
- CRDF N/A
- Revenue
- NECB $104,392,000.00
- CRDF $683,000.00
- Revenue This Year
- NECB $2.80
- CRDF N/A
- Revenue Next Year
- NECB $8.34
- CRDF N/A
- P/E Ratio
- NECB $6.70
- CRDF N/A
- Revenue Growth
- NECB 2.77
- CRDF 39.96
- 52 Week Low
- NECB $16.51
- CRDF $2.01
- 52 Week High
- NECB $31.72
- CRDF $5.64
- Technical
- Relative Strength Index (RSI)
- NECB 60.97
- CRDF 41.22
- Support Level
- NECB $22.85
- CRDF $2.42
- Resistance Level
- NECB $23.95
- CRDF $2.87
- Average True Range (ATR)
- NECB 0.79
- CRDF 0.18
- MACD
- NECB 0.17
- CRDF 0.01
- Stochastic Oscillator
- NECB 90.68
- CRDF 24.42
About NECB NorthEast Community Bancorp Inc.
NorthEast Community Bancorp Inc operates as a community-oriented financial institution. It is principally engaged in the business of attracting deposits and investing those funds into mortgage and commercial loans. It conducts activities throughout the Northeastern United States including New York, Massachusetts, New Jersey, and Connecticut. The company offers a comprehensive line of banking products and services, including mobile banking as well as commercial real estate loans, commercial construction financing, lines of credit, and term loans. It also offers investment advisory and financial planning services.
About CRDF Cardiff Oncology Inc.
Cardiff Oncology Inc is a clinical-stage biotechnology company leveraging PLK1 inhibition, a well-validated oncology drug target, to develop novel therapies across a range of cancers with the greatest unmet medical need. It is focusing on clinical programs in indications such as RAS-mutated metastatic colorectal cancer ("mCRC"), as well as in investigator-initiated trials in metastatic pancreatic ductal adenocarcinoma ("mPDAC"), small cell lung cancer ("SCLC"), and triple negative breast cancer ("TNBC"). Geographically, the company only operates in the United States.